Korro Bio CEO and leadership

Ram Aiyar, Ph.D., MBA, is the chief executive officer of Korro Bio and sits on the board of directors.

Ram brings nearly two decade of diverse experience in biotech and pharma, working across all stages of development from launch to clinical to commercialization. He has a long history of launching and building biotech startups, and previously held a wide range of roles in finance, strategy, product development and venture capital. Most recently, he was a co-founder, chief financial officer and chief business officer at Corvidia Therapeutics, and eventually led its acquisition by Novo Nordisk for $2.1B. Prior to Corvidia, he was an entrepreneur-in-residence at BioHealth Innovation (BHI).

Ram started his scientific career in research at Janssen Pharmaceuticals’ immunology group. He has also held leadership roles in corporate development, finance and strategy at FlowMetric Inc., Sofinnova Partners, and J.P. Morgan Chase.

Ram received his M.S. and Ph.D. in electrical and computer engineering from Drexel University and an MBA in finance and business strategy from INSEAD (France/Singapore).

Andrew Fraley, Ph.D., co-founder and chief technology officer at Korro Bio, brings over 20 years of experience in the field of nucleic acid technologies and therapeutics.

Prior to Korro, Andrew was a co-founder of Triplet Therapeutics, and a founding executive team member serving as SVP of translational sciences for Trucode Gene Repair, an in vivo gene editing company, leading the company’s scientific strategy and operations. He has also served in key senior leadership roles within the biotech community, including Moderna Therapeutics, enabling the development of modified messenger RNA, and Ensemble Therapeutics, providing leadership for platform development and macrocyclic discovery.

Andrew has authored and reviewed scientific publications and is listed as an inventor on patents in areas including nucleic acid therapeutics, oligonucleotide delivery and macrocyclic drug discovery. He has served as a Boston University Kindle Mentor and has consulted for government organizations, venture firms and biotech startups. He holds a B.A. from DePauw University, earned his Ph.D. in bio-organic chemistry at Boston College and was a Chateaubriand Postdoctoral Research Fellow at the Université de Louis Pasteur.

Accomplished, biotech executive with two decades of experience in life sciences industry advancing biopharmaceutical assets, growing companies and creating value. Strategic business partner to senior management and Board of Directors with expertise in corporate development, operations, financing and business development transactions, intellectual property, and compliance.

Vineet Agarwal is a Chief Financial Officer at Korro Bio and is based in City Metropolitan Area, New York City, New York. He has worked as Associate at J.P. Morgan, Executive Director at JPMorgan Chase &, and Vice President at JPMorgan Chase &. Vineet studied at Dr. Virendra Swaroop Public School, Kanpur; Shri Ram College of Commerce between 2000 and 2003; and Institute of Management Technology, Ghaziabad between 2005 and 2007.

Ram Aiyar, Ph.D., MBA, is the chief executive officer of Korro Bio and sits on the board of directors.

Ram brings nearly two decade of diverse experience in biotech and pharma, working across all stages of development from launch to clinical to commercialization. He has a long history of launching and building biotech startups, and previously held a wide range of roles in finance, strategy, product development and venture capital. Most recently, he was a co-founder, chief financial officer and chief business officer at Corvidia Therapeutics, and eventually led its acquisition by Novo Nordisk for $2.1B. Prior to Corvidia, he was an entrepreneur-in-residence at BioHealth Innovation (BHI).

Ram started his scientific career in research at Janssen Pharmaceuticals’ immunology group. He has also held leadership roles in corporate development, finance and strategy at FlowMetric Inc., Sofinnova Partners, and J.P. Morgan Chase.

Ram received his M.S. and Ph.D. in electrical and computer engineering from Drexel University and an MBA in finance and business strategy from INSEAD (France/Singapore).

Andrew Fraley, Ph.D., co-founder and chief technology officer at Korro Bio, brings over 20 years of experience in the field of nucleic acid technologies and therapeutics.

Prior to Korro, Andrew was a co-founder of Triplet Therapeutics, and a founding executive team member serving as SVP of translational sciences for Trucode Gene Repair, an in vivo gene editing company, leading the company’s scientific strategy and operations. He has also served in key senior leadership roles within the biotech community, including Moderna Therapeutics, enabling the development of modified messenger RNA, and Ensemble Therapeutics, providing leadership for platform development and macrocyclic discovery.

Andrew has authored and reviewed scientific publications and is listed as an inventor on patents in areas including nucleic acid therapeutics, oligonucleotide delivery and macrocyclic drug discovery. He has served as a Boston University Kindle Mentor and has consulted for government organizations, venture firms and biotech startups. He holds a B.A. from DePauw University, earned his Ph.D. in bio-organic chemistry at Boston College and was a Chateaubriand Postdoctoral Research Fellow at the Université de Louis Pasteur.

Ram Aiyar, Ph.D., MBA, is the chief executive officer of Korro Bio and sits on the board of directors.

Ram brings nearly two decade of diverse experience in biotech and pharma, working across all stages of development from launch to clinical to commercialization. He has a long history of launching and building biotech startups, and previously held a wide range of roles in finance, strategy, product development and venture capital. Most recently, he was a co-founder, chief financial officer and chief business officer at Corvidia Therapeutics, and eventually led its acquisition by Novo Nordisk for $2.1B. Prior to Corvidia, he was an entrepreneur-in-residence at BioHealth Innovation (BHI).

Ram started his scientific career in research at Janssen Pharmaceuticals’ immunology group. He has also held leadership roles in corporate development, finance and strategy at FlowMetric Inc., Sofinnova Partners, and J.P. Morgan Chase.

Ram received his M.S. and Ph.D. in electrical and computer engineering from Drexel University and an MBA in finance and business strategy from INSEAD (France/Singapore).